$VXRT
Vaxart, Inc.

2024 Q3 Form 10-Q Financial Statement

#000143774924025556 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $4.933M $6.401M
YoY Change 134.79% 371.35%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.342M $5.177M
YoY Change -11.75% -7.52%
% of Gross Profit
Research & Development $15.07M $17.48M
YoY Change 0.43% -7.09%
% of Gross Profit
Depreciation & Amortization $1.000M $900.0K
YoY Change 0.0% -4.66%
% of Gross Profit
Operating Expenses $19.41M $22.66M
YoY Change -2.58% -7.19%
Operating Profit -$14.48M -$16.26M
YoY Change -18.78% -29.48%
Interest Expense $1.022M $416.0K
YoY Change 41.36% -41.49%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$14.06M -$16.45M
YoY Change -19.0% -27.01%
Income Tax $18.00K $21.00K
% Of Pretax Income
Net Earnings -$14.08M -$16.47M
YoY Change -19.08% -26.98%
Net Earnings / Revenue -285.42% -257.24%
Basic Earnings Per Share -$0.06 -$0.09
Diluted Earnings Per Share -$0.06 -$0.09
COMMON SHARES
Basic Shares Outstanding 227.4M 176.8M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $58.71M $62.59M
YoY Change 10.78% -7.82%
Cash & Equivalents $22.04M $43.29M
Short-Term Investments $36.68M $19.31M
Other Short-Term Assets $439.0K $328.0K
YoY Change -87.81% -90.14%
Inventory
Prepaid Expenses
Receivables $591.0K $1.088M
Other Receivables $0.00 $0.00
Total Short-Term Assets $66.46M $71.54M
YoY Change 16.39% 0.38%
LONG-TERM ASSETS
Property, Plant & Equipment $9.476M $10.28M
YoY Change -26.69% -26.14%
Goodwill $4.508M $4.508M
YoY Change 0.18% 0.0%
Intangibles $3.740M $3.923M
YoY Change -16.37% -15.71%
Long-Term Investments
YoY Change
Other Assets $842.0K $851.0K
YoY Change -4.64% -43.57%
Total Long-Term Assets $100.2M $42.21M
YoY Change 106.46% -17.86%
TOTAL ASSETS
Total Short-Term Assets $66.46M $71.54M
Total Long-Term Assets $100.2M $42.21M
Total Assets $166.7M $113.7M
YoY Change 57.77% -7.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.524M $3.587M
YoY Change 88.5% -14.57%
Accrued Expenses $6.764M $6.611M
YoY Change 12.9% 9.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.747M $2.686M
YoY Change 111.31% 198.44%
Total Short-Term Liabilities $80.36M $15.76M
YoY Change 613.21% 13.49%
LONG-TERM LIABILITIES
Long-Term Debt $2.128M $1.591M
YoY Change -53.74%
Other Long-Term Liabilities $421.0K $405.0K
YoY Change 51.44% 54.58%
Total Long-Term Liabilities $421.0K $405.0K
YoY Change 51.44% 54.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $80.36M $15.76M
Total Long-Term Liabilities $421.0K $405.0K
Total Liabilities $98.23M $33.74M
YoY Change 187.89% -10.23%
SHAREHOLDERS EQUITY
Retained Earnings -$464.5M -$450.5M
YoY Change 18.44% 20.19%
Common Stock $533.5M $531.1M
YoY Change 15.04% 15.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $68.44M $80.01M
YoY Change
Total Liabilities & Shareholders Equity $166.7M $113.7M
YoY Change 57.77% -7.26%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$14.08M -$16.47M
YoY Change -19.08% -26.98%
Depreciation, Depletion And Amortization $1.000M $900.0K
YoY Change 0.0% -4.66%
Cash From Operating Activities -$4.201M -$12.03M
YoY Change -71.99% -31.16%
INVESTING ACTIVITIES
Capital Expenditures $9.000K $370.0K
YoY Change -96.9% -18.5%
Acquisitions
YoY Change
Other Investing Activities -$17.03M -$9.294M
YoY Change -424.38% 723.21%
Cash From Investing Activities -$17.04M -$9.664M
YoY Change -442.84% 510.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00K 38.24M
YoY Change 0.0% 175.17%
NET CHANGE
Cash From Operating Activities -4.201M -12.03M
Cash From Investing Activities -17.04M -9.664M
Cash From Financing Activities -10.00K 38.24M
Net Change In Cash -21.25M 16.55M
YoY Change 111.65% -420.92%
FREE CASH FLOW
Cash From Operating Activities -$4.201M -$12.03M
Capital Expenditures $9.000K $370.0K
Free Cash Flow -$4.210M -$12.40M
YoY Change -72.47% -30.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
228119936
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
227431605
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
153959853
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
153452833
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
688331
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
507020
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 pure
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q2 us-gaap Depreciation
Depreciation
900000 usd
us-gaap Depreciation
Depreciation
1800000 usd
CY2023Q2 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 usd
CY2024Q2 us-gaap Goodwill
Goodwill
4500000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
4500000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei City Area Code
CityAreaCode
650
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
VXRT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
227439293
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43285000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34755000 usd
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
19308000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
4958000 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1088000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3008000 usd
CY2024Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
3689000 usd
CY2023Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
0 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4165000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2815000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
71535000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
45536000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10280000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11731000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22652000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24840000 usd
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3923000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4289000 usd
CY2024Q2 us-gaap Goodwill
Goodwill
4508000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
4508000 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
851000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
926000 usd
CY2024Q2 us-gaap Assets
Assets
113749000 usd
CY2023Q4 us-gaap Assets
Assets
91830000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3587000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1584000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6611000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5634000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2872000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2703000 usd
CY2024Q2 vxrt Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
2686000 usd
CY2023Q4 vxrt Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
3803000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
15756000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13724000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15983000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17385000 usd
CY2024Q2 vxrt Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
1591000 usd
CY2023Q4 vxrt Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
2623000 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
405000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
293000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
33735000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
34025000 usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
23000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
15000 usd
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
531029000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
467731000 usd
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
565000 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
366000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-450457000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-409574000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
80014000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
57805000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
113749000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91830000 usd
CY2024Q2 us-gaap Revenues
Revenues
6401000 usd
CY2023Q2 us-gaap Revenues
Revenues
1358000 usd
us-gaap Revenues
Revenues
8582000 usd
us-gaap Revenues
Revenues
2033000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17480000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18813000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36493000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38435000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5177000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5598000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12415000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12223000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
22657000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
24411000 usd
us-gaap Operating Expenses
OperatingExpenses
48908000 usd
us-gaap Operating Expenses
OperatingExpenses
50658000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16256000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23053000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-40326000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-48625000 usd
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
416000 usd
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
711000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
919000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1353000 usd
CY2024Q2 vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
610000 usd
CY2023Q2 vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
188000 usd
vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
1414000 usd
vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
366000 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
5000 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16445000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22531000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40817000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47642000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
21000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
66000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
48000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-16466000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-22550000 usd
us-gaap Net Income Loss
NetIncomeLoss
-40883000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47690000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
184703003
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
139594238
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
176757049
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
137403416
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-16466000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-22550000 usd
us-gaap Net Income Loss
NetIncomeLoss
-40883000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47690000 usd
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-6000 usd
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
46000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-15000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
275000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16472000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22504000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40898000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47415000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
55690000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
312000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2024Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
17000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2555000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-6000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-16466000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
80014000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
57805000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
312000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6671000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
199000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-15000 usd
us-gaap Net Income Loss
NetIncomeLoss
-40883000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
80014000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
89753000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
298000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3927000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
21000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
46000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-22550000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
85073000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
110597000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
298000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6574000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
31000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
275000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47690000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
85073000 usd
us-gaap Net Income Loss
NetIncomeLoss
-40883000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47690000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4390000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4228000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
178000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
220000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6671000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6574000 usd
vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
1414000 usd
vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
370000 usd
vxrt Noncash Revenue Related To Sale Of Future Royalties
NoncashRevenueRelatedToSaleOfFutureRoyalties
3563000 usd
vxrt Noncash Revenue Related To Sale Of Future Royalties
NoncashRevenueRelatedToSaleOfFutureRoyalties
288000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1920000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9000 usd
vxrt Increase Decrease In Unbilled Receivable
IncreaseDecreaseInUnbilledReceivable
3689000 usd
vxrt Increase Decrease In Unbilled Receivable
IncreaseDecreaseInUnbilledReceivable
-0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1275000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2447000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2083000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
105000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1725000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-108000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5723000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33218000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41931000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
501000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1693000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
29187000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
22629000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
15000000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
48200000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14688000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23878000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
199000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
31000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
312000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
298000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56436000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15317000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8530000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2736000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34755000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46013000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43285000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43277000 usd
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
275000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43285000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43277000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
296000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
35000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
281000 usd
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
62600000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Use of Estimates</b> – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Actual results and outcomes could differ from these estimates and assumptions.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Concentration of Credit Risk</b> – Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents, available-for-sale investments and accounts receivable. The Company places its cash, cash equivalents and available-for-sale investments at financial institutions that management believes are of high credit quality. The Company is exposed to credit risk in the event of default by the financial institutions holding the cash and cash equivalents to the extent such amounts are in excess of the federally insured limits. Losses incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any <em style="font: inherit;">one</em> corporate issuer or sector and establishing a minimum allowable credit rating.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p>
CY2024Q2 us-gaap Investments And Cash
InvestmentsAndCash
62609000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
16000 usd
CY2024Q2 vxrt Investments And Cash Fair Value Disclosure
InvestmentsAndCashFairValueDisclosure
62593000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43285000 usd
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
19308000 usd
CY2023Q4 us-gaap Investments And Cash
InvestmentsAndCash
39714000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000 usd
CY2023Q4 vxrt Investments And Cash Fair Value Disclosure
InvestmentsAndCashFairValueDisclosure
39713000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34755000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
4958000 usd
CY2024Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
1088000.000 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q2 vxrt Prepaid Clinical And Manufacturing Expenses
PrepaidClinicalAndManufacturingExpenses
2218000 usd
CY2023Q4 vxrt Prepaid Clinical And Manufacturing Expenses
PrepaidClinicalAndManufacturingExpenses
984000 usd
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
734000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
258000 usd
CY2024Q2 us-gaap Prepaid Rent
PrepaidRent
0 usd
CY2023Q4 us-gaap Prepaid Rent
PrepaidRent
488000 usd
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
885000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
752000 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
328000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
333000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4165000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2815000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18943000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18562000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8663000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6831000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10280000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11731000 usd
CY2024Q2 us-gaap Depreciation
Depreciation
900000 usd
us-gaap Depreciation
Depreciation
1800000 usd
CY2024Q2 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22700000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24800000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5080000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5080000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1157000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
791000 usd
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3923000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4289000 usd
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
365000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
732000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
731000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
731000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
727000 usd
CY2024Q2 vxrt Finitelived Intangible Asset Expected Amortization After Year Four
FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour
637000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3923000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3704000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4576000 usd
CY2024Q2 vxrt Accrued Clinical And Manufacturing Expenses Current
AccruedClinicalAndManufacturingExpensesCurrent
1591000 usd
CY2023Q4 vxrt Accrued Clinical And Manufacturing Expenses Current
AccruedClinicalAndManufacturingExpensesCurrent
312000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
522000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
211000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
794000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
535000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6611000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5634000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2000000 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.098 pure
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M12D
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2209000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4511000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5031000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5207000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5389000 usd
CY2024Q2 vxrt Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
1348000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
23695000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4840000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
18855000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2872000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15983000 usd
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1553000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1553000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
3107000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
3063000 usd
CY2024Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
7000 usd
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
10000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
19000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
31000 usd
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
381000 usd
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
431000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
885000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
942000 usd
CY2024Q2 us-gaap Sublease Income
SubleaseIncome
20000 usd
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
-0 usd
us-gaap Sublease Income
SubleaseIncome
34000 usd
us-gaap Sublease Income
SubleaseIncome
-0 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
1921000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
1994000 usd
us-gaap Lease Cost
LeaseCost
3977000 usd
us-gaap Lease Cost
LeaseCost
4036000 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 vxrt Common Stock Increase In Shares Authorized
CommonStockIncreaseInSharesAuthorized
100000000
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
us-gaap Dividends
Dividends
0 usd
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
45688228
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
27043664
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
688331
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
507020
CY2024Q2 vxrt Class Of Warrant Or Right Expirations In Period
ClassOfWarrantOrRightExpirationsInPeriod
70663
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
140596
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5685806
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17938726
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.9
vxrt Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Decrease From Grants
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantDecreaseFromGrants
7135230
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5226937
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.12
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
26980
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.78
vxrt Sharebased Compensation Arrangement By Sharebased Payment Award Nonoption Equity Instruments Released
SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsReleased
526424
CY2024Q1 vxrt Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Released Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue
1.39
vxrt Share Based Compensation Arrangement By Share Based Payment Award Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeited
1659141
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1286857
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.2
vxrt Share Based Compensation Arrangement By Share Based Payment Award Canceled
ShareBasedCompensationArrangementByShareBasedPaymentAwardCanceled
139252
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
152023
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.2
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
18348969
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
21699803
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.5
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
21699803
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.5
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M2D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
35000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
12175103
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.98
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y6M18D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
35000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21000 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
26980
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17000 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
54720
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
31000 usd
CY2024Q2 us-gaap Share Price
SharePrice
0.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.78
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2555000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3927000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6671000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6574000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-16466000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-22550000 usd
us-gaap Net Income Loss
NetIncomeLoss
-40883000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47690000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
184703003
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
139594238
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
176757049
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
137403416
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25069727
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22738219
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22882059
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19526614

Files In Submission

Name View Source Status
0001437749-24-025556-index-headers.html Edgar Link pending
0001437749-24-025556-index.html Edgar Link pending
0001437749-24-025556.txt Edgar Link pending
0001437749-24-025556-xbrl.zip Edgar Link pending
ex_681173.htm Edgar Link pending
ex_681174.htm Edgar Link pending
ex_681175.htm Edgar Link pending
ex_709042.htm Edgar Link pending
ex_709229.htm Edgar Link pending
ex_709230.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pipelineslide.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vxrt-20240630.xsd Edgar Link pending
vxrt20240630_10q.htm Edgar Link pending
vxrt-20240630_def.xml Edgar Link unprocessable
vxrt-20240630_lab.xml Edgar Link unprocessable
vxrt-20240630_pre.xml Edgar Link unprocessable
vxrt20240630_10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
vxrt-20240630_cal.xml Edgar Link unprocessable